Last reviewed · How we verify

Dose 2 of glycopyrronium, 3.75% QD

Journey Medical Corporation · Phase 2 active Small molecule

Dose 2 of glycopyrronium, 3.75% QD is a Small molecule drug developed by Journey Medical Corporation. It is currently in Phase 2 development. Also known as: DRM04.

At a glance

Generic nameDose 2 of glycopyrronium, 3.75% QD
Also known asDRM04
SponsorJourney Medical Corporation
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dose 2 of glycopyrronium, 3.75% QD

What is Dose 2 of glycopyrronium, 3.75% QD?

Dose 2 of glycopyrronium, 3.75% QD is a Small molecule drug developed by Journey Medical Corporation.

Who makes Dose 2 of glycopyrronium, 3.75% QD?

Dose 2 of glycopyrronium, 3.75% QD is developed by Journey Medical Corporation (see full Journey Medical Corporation pipeline at /company/journey-medical-corporation).

Is Dose 2 of glycopyrronium, 3.75% QD also known as anything else?

Dose 2 of glycopyrronium, 3.75% QD is also known as DRM04.

What development phase is Dose 2 of glycopyrronium, 3.75% QD in?

Dose 2 of glycopyrronium, 3.75% QD is in Phase 2.

Related